Comparative Pharmacology
Head-to-head clinical analysis: TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE versus VONTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE versus VONTROL.
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE vs VONTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trimethobenzamide is a centrally acting antiemetic that inhibits the chemoreceptor trigger zone (CTZ) in the medulla oblongata by suppressing emetic stimuli. Its exact mechanism is not fully understood but may involve antagonism of dopamine D2 receptors and possibly serotonin 5-HT3 receptors.
VONTROL (trimethobenzamide) acts centrally to inhibit the chemoreceptor trigger zone (CTZ) in the medulla oblongata, thereby suppressing nausea and vomiting. Its exact mechanism is not fully understood but may involve antagonism of dopamine D2 receptors and serotonin 5-HT3 receptors.
300 mg orally or intramuscularly 3 to 4 times daily as needed for nausea and vomiting.
10 mg orally twice daily; maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life approximately 7-9 hours in adults; prolonged in renal impairment (up to 20-30 hours).
12 hours; prolonged in renal impairment (up to 24 hours in ESRD)
Primarily renal (50-70% as unchanged drug and metabolites) and biliary (~20-30%); less than 5% fecal.
Renal: 60% unchanged; fecal: 30% (biliary); hepatic metabolism: 10%
Category C
Category C
Antiemetic
Antiemetic